Introduction
The retinol derivative 13-cis retinoic acid (13-cisRA) is now an established component of the treatment of high-risk neuroblastoma [1] . Low-dose 13-cisRA previously showed limited clinical benefit in patients with recurrent disease. Administration of 13-cisRA at a higher dose of 160 mg/m 2 /day and use of an intermittent regimen in a Children's Cancer Group phase III randomized trial showed significant improvement in 3-year event-free survival (EFS) [2] . Thus, dose intensity and corresponding drug exposure in patients treated with 13-cisRA may represent important determinants of drug efficacy in this scenario [3] . There is potential for optimizing retinoid treatment through adaptive dosing approaches in a neuroblastoma clinical setting, owing to the observed large degree of inter-patient variability in drug disposition and narrow therapeutic window for toxicity versus efficacy [4, 5] .
While 13-cisRA is an established component for treatment of high-risk neuroblastoma, its administration in paediatric patients may cause altered or reduced exposure in patients who are unable to swallow the capsules. This is particularly an issue in a disease such as neuroblastoma where the majority of patients being treated are less than 5 years of age. In these patients, the contents are routinely extracted and mixed with ingestible food or drink, as previously described in UK patient populations [1, 5] .
Retinoids are also known to undergo autoinduction, a phenomenon associated with disease relapse in acute promyelocytic leukaemia patients treated with all-trans retinoic acid (ATRA). Similar autoinduction has also been described for 13-cisRA which might necessitate an adaptive dosing approach in neuroblastoma patients [5, 6] . Drug metabolism studies have shown that 13-cisRA is a substrate for CYP2C8 and UDP glucuronyltransferase, and therefore, genetic polymorphisms of genes coding these enzymes may have an effect on the disposition and plasma concentration of 13-cisRA [5, 7, 8] .
The current study was designed to evaluate the pharmacokinetics of 13-cisRA, establish its correlation with treatment outcomes and study the impact of certain genetic polymorphisms on 13-cisRA disposition in an Indian patient population.
Materials and methods

Patients and setting
Study protocols were approved by the Institutional Review Board (IRB) and written informed consent was obtained from patients and their parents/guardians as appropriate. Patients up to 16 years of age who were receiving 13-cisRA as part of standard clinical treatment for high-risk neuroblastoma at our centre were eligible to participate in the study. The standard treatment comprised of induction chemotherapy (cisplatin, carboplatin, vincristine, etoposide and cyclophosphamide) followed by surgery, autologous bone marrow transplantation and radiotherapy, prior to starting 13-cisRA. Demographic data including age, weight and height were recorded for each patient. The baseline Hb, WBC, platelet counts and the most recent ALT, serum transaminases, bilirubin and creatinine were documented prior to 13-cisRA treatment. Details of 13-cisRA administration and concomitant medications being administered prior to and/or in combination with 13-cisRA were recorded.
Patients with progressive disease after consolidation regimen, those not likely to show compliance to the study medication, those who consumed grapefruit or grapefruit products less than 1 week before sample collection for pharmacokinetic analysis or those receiving any medication which is a known CYP2C8 enzyme inducer or inhibitor (including omeprazole, montelukast, trimethoprim and rifampicin) less than 14 days prior to participation in the study, were excluded from the trial.
Treatment regimen for paediatric patients
13-cisRA (Isotroin 10/20 mg soft gel capsules, Cipla, India) was administered orally at a dose of 160 mg/m 2 /day in two divided doses for 14 days every 28 days for 6 cycles. For patients who were unable to swallow 13-cisRA capsules, each capsule was punctured, and the contents were mixed with water. All patients and/or parents were adequately trained on drug administration, especially those who required the capsules to be punctured and administered. The child's parent/guardian would observe the clinical research coordinator (CRC) prepare the morning dose of 13-cisRA on day 1 of cycle 1. The evening dose would be prepared and administered by the parent/guardian under the CRC's supervision. Subsequent doses were administered at home by the parent/ guardian until the next hospital visit for pharmacokinetic sampling. Administration of 13-cisRA on the days of pharmacokinetic sampling was performed in hospital under supervision.
Blood sampling and analysis
Pharmacokinetic blood samples were collected on day 1 and 14 of cycle 1 and 4 at 0, 1, 2, 4 and 6 h after the morning dose. Blood samples (4 mL) were collected in heparinised tubes and centrifuged at 1200g for 10 min at 4 °C. Plasma was separated and frozen at −20 °C, before analysis using a high-performance liquid chromatography (HPLC) assay. All blood and plasma samples were stored protected from light, and all sample handling was carried out in dim light. The assay was validated with regard to linearity, reproducibility and stability of the analytes according to bioanalytical method validation guidelines of the FDA [9] . The assay was also cross-validated against the method employed at Newcastle University, where several large clinical trials have been conducted and published [1, 5] , by analysing three blinded spiked samples in the low, mid and high range of the 13-cisRA linearity curve.
A HPLC system consisting of a Dionex UHPLC Ultimate model 3000 (Dionex, USA) connected to a UV/ visible absorbance detector (Dionex) was used for sample analysis. Chromatographic separations were performed using a reverse-phase HPLC column [C18 (5 μm, 250 × 4.6 mm i.d., Merck, USA)]. 13-cisRA was detected by the UV-Vis absorbance at 360 nm. The mobile phase used was composed of 40 % acetonitrile, 17 % sodium dihydrogen orthophosphate and 43 % methanol at a flow rate of 1.7 mL/min. The injection volume was 20 μL, and the column was maintained at 40 °C.
Toxicity assessment
Toxicity was assessed in all patients who received at least a single dose of the drug. Adverse effects were graded as per the CTCEA version 3.00. All patients underwent routine biochemistry tests and blood count assessment before the start of each cycle. Any laboratory abnormalities were documented in addition to any side effects or dose interruptions experienced in the previous cycle.
Pharmacogenetics
A 3-mL blood was collected in an EDTA tube at the beginning of treatment for pharmacogenetic analysis. DNA was extracted from leucocytes using a QIAamp DNA Blood Mini Kit (QIAGEN) and quantified using a NanoDrop ND-1000 UV-Vis Spectrophotometer. The frequency of allelic variations for *2, *3 and *4 variants of CYP2C8 was investigated by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. After PCR amplification, 5 μl of the diluted PCR product (1:10) was digested with appropriate restriction enzymes before electrophoresis using 3 % agarose gel. Gene polymorphisms for UGT2B7, CYP3A5*3 and CYP3A7*2 were assessed using TaqMan ® probes. The primers and TaqMan 
Statistical analysis
Pharmacokinetic parameters including C max , AUC, T max and half-life were analysed descriptively using WinNonlin version 6.0. 13-cisRA AUC values determined on C1D1 versus C1D14, and in patients who swallowed capsules versus those patients where capsules were punctured on C1D1, were compared using paired and unpaired t tests, respectively. The median event-free survival (EFS) was estimated from Kaplan-Meier plots, and survival was compared using the log-rank test. Linear regression analysis was performed to assess significant covariates which may affect AUC.
Results
Demographic information
Thirty-five children with high-risk neuroblastoma including 26 males and 9 females, with a median age of 5 years (range 1-13), were enroled over a 4-year period between April 2010 and May 2014. A summary of the demographic data of all patients studied is shown in Table 1 . A flow chart depicting the process of patient screening, enrolment and evaluation is shown in Online Resource 1. Eighteen patients were able to swallow the capsules. For 16 patients, the capsules had to be punctured and the contents mixed with a teaspoonful of water for administration.
Pharmacokinetics and toxicity
A marked level of inter-patient variability in 13-cisRA pharmacokinetics was observed (CV, C1D1 AUC 0-6h = 121 %). There was a trend towards a higher AUC 0-6h on day 1 as compared to day 14 in both treatment cycles studied. Pharmacokinetic parameters for all patients are shown in Table 2 weight, gender and age were not found to have any significant effect on exposure to the drug. Twenty-four out of 36 patients (67 %) in cycle 1 reported Grade 1 toxicity such as vomiting (n = 2), dryness of skin and mild itching (n = 10), chelitis and stomatitis (n = 7), and skin lesions (n = 7). Severe Grade 2 chelitis (n = 3) and skin lesions (n = 3) were also observed in cycle 1. In cycle 4, 16 out of 19 patients (84 %) were affected by Grade 1 toxicity such as vomiting (n = 1), dryness of skin, peeling and mild itching (n = 13), chelitis (n = 5) and skin lesions (n = 3). Two patients reported Grade 2 toxicity such as severe chelitis and peeling of skin all over the body associated with itching. Only one patient reported Grade 3 toxicity of extensive skin lesions with severe itching. It is interesting to note that this patient exhibited the highest AUC and C max on all courses of treatment studied. However, no clear correlation was observed between drug exposure and toxicity.
Pharmacogenetics
Pharmacogenetic associations were evaluated in 22 patients, for whom concomitant pharmacokinetic data were available. Six SNPs were analysed in four genes of putative relevance for 13-cisRA disposition. None of the patients carried CYP2C8*2/*3/*4 or CYP3A5*3 variants. Eleven out of 22 children were heterozygous for CYP3A7*2 allele. When these data were combined with data for the selected SNPs from 72 patients recruited to the recently published UK study [5] , no significant association was found between the various genotypes and C max for C1D14 (Fig. 2) .
Survival data
The median event-free survival (EFS) was 8 months. Patients who were event free at 1 year tended to have higher 13-cisRA AUC 0-6h on C1D1 compared to those who progressed or died (23.3 ± 8.79 vs. 9.00 ± 3.86 µM h). However, the difference was not statistically significant. Patients who achieved maximum plasma concentration ≥2 µM on C1D1 had a trend towards higher median EFS compared to those who did not (16.98 vs. 8.05 months). Similarly, this difference was not statistically significant (Online Resource 2).
Discussion
Recent data have been published relating to the potential clinical importance of 13-cisRA pharmacokinetic variability in neuroblastoma patients, but only in European and US patient populations [1, 5, 6] . The current study was designed to address how the published data compared to results obtained from an Indian neuroblastoma population. Fig. 1 Plasma concentrations of 13-cisRA observed on day 1 of course 1 of treatment in patients who swallowed the capsules versus those patients for whom the contents were extracted and administered with water. The difference in exposure (AUC) was statistically significant (21.53 ± 5.05 vs. 9.35 ± 2.78 µM h, P < 0.05)
Cross-validation of the assays used to analyse clinical samples in India and the UK was carried out to ensure the integrity of the data obtained. It was observed that the estimates of clearance and volume of distribution were comparable between UK and Indian neuroblastoma populations, except for markedly higher variability observed in Indian patients as compared to the UK cohort. In spite of the marked variability in pharmacokinetic parameters, none of the known covariates affected drug exposure in the linear regression analysis, suggesting that multiple factors govern the disposition of 13-cisRA. A number of cytochrome P450 (CYP) enzymes have been identified as playing a role in the metabolism of 13-cisRA, with CYP2C8 identified as the most important in terms of activity and level of expression in the liver [7, 8] . In the Caucasian population, the allele frequencies for CYP2C8*3, CYP2C8*4, CYP3A5*3 and UGT2B7*2 were 8.9, 2.8, 91.8 and 49.3 %, respectively [5, 8] . Genetic polymorphisms for CYP2C8*2/*3/*4 or CYP3A5*3 variants were not detected in this study. In total, 50 % of our patient population were heterozygous for CYP3A7*2 allele, as opposed to an allele frequency of 6.2 % in the Caucasian population, as reported in the UK study. Although the occurrence of polymorphisms is variable amongst the populations, no significant impact was observed on the metabolism or exposure of 13-cisRA when these data were combined. From the current and published findings, it suggests that genetic variation in the CYP and UGT genes investigated does not play a significant role in influencing the pharmacokinetics of 13-cisRA in a neuroblastoma patient setting. While a larger study should be carried out, taking into account genetic differences that may be prevalent between Caucasian and Asian populations, the data presented are supportive of previously published findings in this area [5] .
Although the current study involves a relatively limited number of patients, it clearly shows that the level of interpatient pharmacokinetic variability previously observed following 13-cisRA treatment in UK and US studies is replicated in an Indian patient population. Incidentally, our findings suggest a potential association between drug exposure and EFS. However, confirmatory studies should be undertaken to validate these findings due to the small number of patients studied.
With a median age of 4 years, route of 13-cisRA dose administration in a neuroblastoma setting poses a serious practical challenge as the majority of patients are unable to swallow the capsules. This results in lower plasma retinoid concentrations, often below the proposed therapeutic threshold of 2 µM [5] . These children are likely to benefit from a higher 13-cisRA dose. The data from Veal et al. [5] also support similar dose modifications in children who are unable to swallow 13-cisRA capsules. More importantly, it highlights the need for a paediatric friendly liquid formulation of 13-cisRA to achieve optimal levels of the drug in plasma [3] . In a recent review, Bauters et al. [10] have discussed the practical implications for the administration of 13-cis retinoic acid in children. The EMEA also acknowledges the need for an appropriate formulation of 13-cisRA that is suitable for children, since the large capsules of 13-cisRA are difficult for small children to swallow [11] . Our data confirm that this is a global problem and not one relevant only to Western patient populations.
In addition, the mean AUC of 13-cisRA was approximately 30 % lower on day 14 of treatment as opposed to day 1 in both cycles. This difference, however, was not statistically significant. While this trend might point towards the phenomenon of autoinduction, determination of the 4-oxo-13-cisRA metabolite concentration in patient samples would have been more conclusive. Interestingly, Veal et al. [1] reported accumulation of the 4-oxo metabolite between days 1 and 14 of treatment but did not observe a corresponding decrease in the plasma concentrations of the parent drug. However, both 13-cisRA and its 4-oxo metabolite are reported to be equipotent at inhibiting human neuroblastoma cell lines in vitro [12] , and therefore, the phenomenon of autoinduction may be less clinically relevant for 13-cisRA.
To conclude, high inter-patient variability was observed in 13-cisRA pharmacokinetics. Further, it could be a candidate for therapeutic drug monitoring practices if the suggested exposure-effect relationship is established in a confirmatory trial. Children who cannot swallow capsules risk reduced drug exposure which could affect treatment outcomes. These data highlight that administration of this drug is a worldwide problem and needs to be addressed. The findings can also be contrasted to a drug such as vincristine, where markedly different pharmacokinetics have been shown between UK Wilms tumour patients and comparable patients studied in Malawi [13] . Clearly, therefore, it will be challenging to draw conclusions concerning potential differences in the clinical pharmacology of a wide spectrum of different anticancer drugs, between developing countries and the USA and Europe, without conducting well-designed studies. It is important that such studies include the cross-validation of appropriate assays in order to accurately compare data generated in different laboratories and that collaborative pharmacogenetic studies are carried out to obtain the patient numbers required for the generation of clinically meaningful data.
